Background Chronic graft-versus-host disease (GVHD) is the leading cause of later illness
and death after allogeneic hematopoietic stem-cell transplantation. We hypothesized that …

Purpose Several open-label randomized studies have suggested that in vivo T-cell
depletion with anti–T-lymphocyte globulin (ATLG; formerly antithymocyte globulin …

Previous randomized graft-versus-host disease (GVHD)-prophylaxis trials have failed to
demonstrate reduced incidence and severity of chronic GVHD (cGVHD). Here we …

This retrospective report assessed the impact of rabbit antithymocyte globulins (ATG),
incorporated within a standard myeloablative conditioning regimen prior to allogeneic stem …

Background Previously, we demonstrated that the addition of anti-human-T-lymphocyte
immunoglobulin (ATLG) to standard ciclosporin and methotrexate prophylaxis reduced graft …

Background Pretreatment with anti-thymocyte globulin (ATG) decreases the occurrence of
chronic graft-versus-host disease (CGVHD) after haemopoietic cell transplantation from an …

Background Anti-thymocyte globulin (ATG) is used to prevent graft-versus-host disease
(GvHD) after allogeneic haemopoietic cell transplantation (HCT). However, ATG can also …

Anti-T-cell lymphocyte globulin (ATLG) and posttransplant cyclophosphamide (PTCy) are
now widely used strategies to prevent graft-versus-host disease (GVHD) after allogeneic …

Antilymphocyte/thymocyte globulins (ALGs/ATGs) have now been used for over 30 years in
the setting of hemopoietic stem cell transplants (HSCT), with the aim of preventing graft …

A total of 155 patients with acute myeloid leukemia (AML) received hematopoietic stem cell
transplants from unrelated donors after standard conditioning. Clinical outcome after the use …